Accounting for 50–60% of all breast cancer diagnoses [3], LumA is the most prevalent subtype and is associated with relatively good clinical outcomes and prognosis; however, a mechanistic understanding of LumA pathogenesis and the development of novel chemotherapies remain critical. Here, TMEM43 is linked to breast carcinoma.